欧州アレルギー・臨床免疫学会2024 (EAACI Congress 2024)：アレルギー治療の革新と進歩
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
学会中は、環境科学の進歩、食物アレルギー、免疫療法の革新、小児アレルギーなどに焦点を当てた、150を超える科学セッションが開催される。精密医療、AI、免疫療法、免疫調節剤が、最大規模のアレルギーおよび免疫学学会に集結。同学会は、5月31日から6月3日までスペインのバレンシアで開催される。 スペイン、バレンシア発, April 30, 2024 (GLOBE NEWSWIRE) --...
Kongres EAACI 2024: Inovasi dan Kemajuan dalam Pengobatan Alergi
30 avr. 2024 02h58 HE
|
European Academy of Allergy and Clinical Immunology
Lebih dari 150 sesi ilmiah akan dipresentasikan selama pelaksanaan kongres, dengan fokus di berbagai bidang yang di antaranya mencakup kemajuan dalam sains lingkungan, alergi makanan, inovasi...
Medigene AG reports Financial Results and Business Update for Q1 2024
26 avr. 2024 03h00 HE
|
Medigene AG
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
25 avr. 2024 09h00 HE
|
Medigene AG
Planegg/Martinsried, April 25, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
24 avr. 2024 07h00 HE
|
Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Medigene to Present at Upcoming Scientific Conferences
17 avr. 2024 06h00 HE
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been...
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
08 avr. 2024 02h00 HE
|
Medigene AG
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Secures European Patent for its iM-TCR Technology
04 avr. 2024 05h00 HE
|
Medigene AG
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
28 mars 2024 02h30 HE
|
Medigene AG
Significant corporate and scientific progress in 2023Innovations to End-to-End Platform technologies and IP portfolioPipeline additions with multiple KRAS neoantigen targetsAdvancement of lead program...
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
19 mars 2024 09h00 HE
|
Medigene AG
Planegg/Martinsried, March 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...